Market Overview

Oppenheimer Initiates Tonix Pharmaceuticals With Outperform

Related CNS
Benzinga's Top Initiations
Cohen & Steers Initiated At Credit Suisse, Sees Organic Growth Through 2017
Cohen & Steers' (CNS) CEO Robert Steers on Q3 2016 Results - Earnings Call Transcript (Seeking Alpha)

Oppenheimer initiated coverage on Tonix Pharmaceuticals (NYSE: TNXP) with an Outperform rating.

The target price is set to $18.

Editor's note: A previous version of this article incorrectly stated that Oppenheimer initiated coverage on Cohen & Steers, Inc. (NYSE: CNS) with a Outperform rating.

Latest Ratings for CNS

Oct 2016Keefe Bruyette & WoodsMaintainsMarket Perform
Jul 2016Credit SuisseInitiates Coverage onNeutral
Jul 2016Credit SuisseInitiates Coverage onNeutral

View More Analyst Ratings for CNS
View the Latest Analyst Ratings

Posted-In: OppenheimerInitiation Analyst Ratings


Related Articles (CNS)

View Comments and Join the Discussion!